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DOI 10.1016/j.ccr.2010.07.010SUMMARYMDM2, a negative regulator of p53, is elevated in many cancers that retain wild-type p53. A single nucleotide
polymorphism (SNP) in the humanMDM2 promoter increases the affinity of Sp1 resulting in elevated MDM2
levels. We generated mice carrying either theMDM2SNP309T or theMDM2SNP309G allele to address the impact
of MDM2SNP309G on tumorigenesis. Mdm2SNP309G/G cells exhibit elevated Mdm2 levels, reduced p53 levels,
and decreased apoptosis. Importantly, some Mdm2SNP309G/G mice succumbed to tumors before 1 year of
age, suggesting that this allele increases tumor risk. Additionally, the Mdm2SNP309G allele potentiates the
tumor phenotype and alters tumor spectrum in mice inheriting a p53 hot-spot mutation. These data provide
causal evidence for increased cancer risk in carriers of the Mdm2SNP309G allele.INTRODUCTION
Ablation of the p53 tumor suppressor pathway is a hallmark
of tumorigenesis as evidenced by the fact that p53 is the
most commonly mutated or inactivated tumor suppressor in
neoplastic malignancies. p53 encodes a transcription factor
that activates numerous cell cycle arrest, senescence, and
apoptotic genes (Vogelstein et al., 2000). Mutations in or dele-
tions of the p53 gene occur in >50% of human cancers (Soussi
and Lozano, 2005). In cancers lacking p53 mutations, other
components of the p53 pathway are altered during tumorigen-
esis, contributing to the functional inactivation of the p53
pathway (Soussi and Lozano, 2005). Most notably, the MDM2
gene is amplified in >30% of sarcomas and the MDM2 proteinSignificance
Proper regulation of the homeostatic balance between p53 an
polymorphicMDM2SNP309G allele in humans, which alters this d
this SNP in accelerating tumorigenesis. There have been numer
in the clinic. To directly assess the impact ofMdm2SNP309, we
Mdm2SNP309G orMdm2SNP309T alleles and monitored these mic
alleles have an attenuated p53 pathway resulting in a shorter
results demonstrate the Mdm2SNP309G allele has a direct impa
220 Cancer Cell 18, 220–230, September 14, 2010 ª2010 Elsevier Inis overexpressed in multiple human cancers that retain wild-
type p53 (Oliner et al., 1992; Valentin-Vega et al., 2007). Mdm2
is a protooncogene that encodes an E3 ubiquitin ligase that
negatively regulates p53 protein stability and transcriptional
activity (Iwakuma and Lozano, 2003). These data underscore
the fact that decreased levels of p53, resulting from mutations
in the p53 gene or alterations in the stoichiometry of its inhibitor
MDM2 play a critical role during tumor development.
A T-to-G single nucleotide polymorphism (SNP) in the second
promoter (P2) of the human MDM2 gene (SNP309G) has been
identified (Bond et al., 2004). This SNP is present in the heterozy-
gous state (G/T) in 40% and in the homozygous state (G/G)
in 15% of healthy individuals, respectively (Bond et al., 2006).
MDM2SNP309G enhances the binding of the transcriptionald Mdm2 is critical in tumorigenesis. The identification of the
elicate balance, has lead to an intense focus on the impact of
ous conflicting reports regarding the importance of this SNP
generated cohorts of mice that either carry the polymorphic
e for tumor development. Mice harboring twoMdm2SNP309G
latency to tumor formation and decreased survival. These
ct on cancer risk.
c.
Figure 1. Generation of Mice Containing
Either the Humanized Mdm2SNP309G or
Mdm2SNP309T Allele
(A) The targeting vectors were designed to incor-
porate the PGK-neo selectable marker in intron 3
flanked by loxP sites (triangles) containing the
entire human intron 1 (hIn1) with a G or T nucleo-
tide at SNP309 (denoted by an asterisk). Black
numbered boxes denote Mdm2 exons. After Cre-
mediated recombination, the PGK-neo cassette
was deleted.
(B) Southern blot analysis of SpeI-digested
DNA from ES cell clones electroporated with
the Mdm2SNP309G or the Mdm2SNP309T targeting
vectors. The 23-kb SpeI fragment represents the
wild-typeMdm2 allele whereas the 12.5-kb SpeI fragment is the expected size for the recombined allele using a 50 probe.Wild-type (WT) DNA serves as a control.
The 9.5-kb SpeI fragment is the expected size for the recombined alleles using a 30 probe. See also Figure S1.
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tive increase in MDM2 transcription. This in turn leads to
increased levels of the MDM2 protein and therefore decreased
p53 protein levels. Most importantly, the MDM2SNP309G allele
has been associated with an increased cancer risk in some
human tumors that express wild-type p53 (Bond et al., 2006;
Dharel et al., 2006; Grochola et al., 2010; Yarden et al., 2008).
However, a significant number of reports have failed to corrobo-
rate such a notion (Krekac et al., 2008; Khan et al., 2008). Clinical
correlates aimed at supporting the effect of the MDM2SNP309G
allele in humans with spontaneous cancers have been contro-
versial, likely as a result of the heterogeneity of the employed
data sets and the retrospective nature of these analyses (Bond
et al., 2006; Bond and Levine, 2007; Copson et al., 2006; Dharel
et al., 2006; Economopoulos and Sergentanis, 2009; Ellis et al.,
2008; Grochola et al., 2010; Menin et al., 2006; Schmidt et al.,
2007; Yarden et al., 2008).
Additional support of an enhanced cancer risk inMDM2SNP309
carriers is the fact that patients diagnosed with Li-Fraumeni
syndrome (LFS) with an inherited germline mutation in p53
and homozygous for the G nucleotide at MDM2SNP309develop
tumors approximately 10 years earlier than LFS patients lacking
this polymorphism (Bond et al., 2004; Bougeard et al., 2006;
Marcel et al., 2009; Ruijs et al., 2007; Tabori et al., 2007). Addi-
tionally, patients with LFS carrying two MDM2SNP309G alleles
are more frequently diagnosed with multiple primary tumors
compared to LFS patients carrying two MDM2SNP309T alleles.
Together, these data suggest an enhanced cancer phenotype
in patients carrying germline-inactivating mutations in p53 and
MDM2SNP309G. Thus, increased MDM2 levels resulting from the
presence of theMDM2SNP309G allele may further down modulate
an already muted p53 pathway. These data are however correl-
ative by nature.
Recent attempts to understand the mechanisms that regulate
the Mdm2-p53 pathway during tumorigenesis have focused on
the generation of mouse models that genetically delete p53,
overexpress genes that regulate p53, or produce mutant p53
proteins that mimic human mutations (Donehower and Lozano,
2009). Additionally, though, more subtle changes also affect
tumorigenesis. For example, haploinsufficiency at the Mdm2
locus delays tumor onset in mice carrying an Em-myc transgene
and also renders mice sensitive to DNA damage (Alt et al., 2003;
Mendrysa et al., 2003; Terzian et al., 2007). However, little isCanknown about the impact of more subtle genetic modifiers that
affect the regulation or expression of proteins involved in tumor-
igenesis. In this study, we have used the naturally occurring poly-
morphism in the MDM2 promoter to generate two humanized
Mdm2SNP309 murine alleles to examine the direct impact of this
polymorphism on tumor development.
RESULTS
Generation of Mdm2SNP309 Mice
To directly test the significance of Mdm2SNP309 in a prospective
manner, we generated humanized Mdm2SNP309 alleles in
the mouse. Using a PCR-based strategy, we generated
Mdm2SNP309G andMdm2SNP309T targeting constructs by replac-
ing the mouse intron 1 (containing the entire P2 promoter)
with the corresponding human intron 1 with either the G or T
polymorphism. Both targeting constructs were sequenced in
their entirety to rule out the presence of additional changes.
MDM2SNP309G and MDM2SNP309T human intron 1 sequences
are identical, except for the polymorphism (Figure S1A available
online). The polymorphisms were introduced into the murine
Mdm2 locus by homologous recombination in embryonic stem
(ES) cells (Figure 1A). Southern blot analysis of the recombination
event revealed correct targeting of both constructs at the murine
Mdm2 locus (Figure 1B). Additionally, Southern blot analysis
using a probe against the neomycin cassette verified single
copy integration and indicated the absence of other insertions
(Figures S1B and S1C). Chimeric mice were backcrossed with
C57Bl/6 mice for five generations, including one cross with
Zp3-Cre mice (also in a C57Bl/6 background) that resulted in
Cre-loxP-mediated excision of the PGK-neomycin cassette.
A cohort ofMdm2SNP309G/G andMdm2SNP309T/Tmice was estab-
lished for tumor studies. The background of all mice used in
these studies is >98% C57Bl/6.
Mdm2 mRNA Levels Are Increased in Tissues
from Mdm2SNP309G/G Mice
To characterize the polymorphic alleles, we first measured
the total level of Mdm2 mRNA in Mdm2SNP309 mice. Real-
time RT-PCR revealed that the spleens and thymi (two p53
sensitive tissues) of 6-week-oldMdm2SNP309G/Gmice had signif-
icantly higher levels of Mdm2 mRNA (2.08 ± 0.37 and 3.7 ± 1.1,
spleens and thymi, respectively) as compared to the controlcer Cell 18, 220–230, September 14, 2010 ª2010 Elsevier Inc. 221
Figure 2. Mdm2SNP309G/G Mice Have Higher
Levels of Mdm2 mRNA as Compared to
Mdm2SNP309T/T and C57Bl/6 Mice
(A) Real-time RT-PCR analysis for Mdm2
mRNA levels in spleen, brain, thymus, and uterus
of C57Bl/6 (C), Mdm2SNP309G/G (G/G), and
Mdm2SNP309T/T (T/T) mice. The mean and stan-
dard error of the mean (SEM) were determined
from triplicate samples after normalization to
Rplp0 for the number (n) of mice indicated. Statis-
tical significance in the spleen (p = 0.032) and
thymus (p = 0.031) was determined by one-way
analysis of variance (ANOVA).
(B) RNase protection analysis for Mdm2 mRNA
levels in spleen ofMdm2SNP309G/G andMdm2SNP309T/T mice. Schematic of theMdm2 locus and RNase protection probe. P1 (transcript from promoter 1), upper
band and P2 (transcript from promoter 2), lower band. Fold change was determined by calculating the ratios of P2/P1 in each sample. See also Figure S2.
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Mdm2SNP309G Directly Influences Cancer RiskMdm2SNP309T/T (1.05 ± 0.43 and 0.95 ± 0.41, spleens and thymi,
respectively) and wild-type C57Bl/6 (that carry the endogenous
murine intron 1) (0.98 ± 0.12 and 0.81 ± 0.18, spleens and thymi,
respectively) mice. The levels of Mdm2 in the Mdm2SNP309G/G
tissues were significantly higher than in control mice (p = 0.032
and p = 0.031, spleen and thymus respectively, one-way anal-
ysis of variance [ANOVA]) (Figure 2A). Likewise, the brains and
uteri of 6-week-old Mdm2SNP309G/G mice had higher levels of
Mdm2, although not statistically significant, as compared to
control mice (Figure 2A). RNase protection assays were subse-
quently used to quantitate and distinguish the otherwise identical
transcripts arising from the basal (P1) and P2 promoters (the
second promoter that has the MDM2SNP309). Data show a 2.2-
fold increase in Mdm2 levels from the P2 promoter in spleens
taken fromMdm2SNP309G/Gmice as compared to those obtained
fromMdm2SNP309T/Tmice (Figure 2B). The levels ofMdm2mRNA
from the P1 promoter were unchanged in both Mdm2SNP309G/G
and Mdm2SNP309T/T mice (Figure 2B). These data were further
validated using real time RT-PCR primers specific to the tran-
script generated from the P1 promoter. No significant difference
was noted in the levels of P1 Mdm2 mRNA in C57Bl/6 (0.86 ±
0.12), Mdm2SNP309G/G (1.16 ± 0.28), and Mdm2SNP309T/T (1.16 ±
0.15) mice (ANOVA, p = 0.469; Figure S2). These data indicateFigure 3. Mdm2 Levels Are Higher inMdm2SNP309G/GMouse Embryonic
(A) Real time RT-PCR analysis for transcriptional activation of Mdm2 in Mdm2SN
least three separate embryos per genotype. MEFs were either untreated or treated
(SEM) were determined from triplicate samples after normalization to Rplp0 for t
(B) Western blots of untreated or 500 nMmithramycin A-treatedMdm2SNP309G/G a
antibodies. Lysates from IR treated Mdm2-transgenic (+) and Mdm2/ p53/ M
(C) Cell proliferation rates ofMdm2SNP309G/G andMdm2SNP309T/TMEFs. Three sep
or 5 days, and then assayed for cell number. Each data point represents the me
222 Cancer Cell 18, 220–230, September 14, 2010 ª2010 Elsevier Inthat the increased levels of Mdm2 in vivo are specifically due
to the presence of Mdm2SNP309G in the P2 promoter.
Mdm2 Levels inMdm2SNP309G/G Mouse Embryonic
Fibroblasts Are Sensitive to the Sp1 Inhibitor
Mithramycin A
In humans cell lines the MDM2SN309 polymorphism creates
a stable binding site for the transcription factor Sp1 (Bond
et al., 2004). Mithramycin A disrupts the activity of Sp1, and
treatment of MDM2SNP309G/G human cells with mithramycin A
resulted in a decrease in Mdm2 levels (Bond et al., 2004; Chien
et al., 2010). We therefore assessed the impact of mithramycin
A on Mdm2 mRNA and protein levels. The levels of Mdm2
were significantly reduced in Mdm2SNP309G/G mouse embryo
fibroblasts (MEFs) on mithramycin A treatment (0.98 ± 0.03
and 0.19 ± 0.18, untreated versus treated, respectively, p <
0.0001) (Figure 3A). Western blot analysis revealed that
Mdm2SNP309G/G MEFs had lower levels of Mdm2 protein after
mithramycin A treatment (Figure 3B). Mithramycin A did not
significantly alter the levels of Mdm2 in Mdm2SNP309T/T MEFs,
although the Mdm2 levels in the untreated Mdm2SNP309T/T
MEFs were much lower than the untreated Mdm2SNP309G/G
MEFs (Figure 3A and B). Thus, although the basal levels ofFibroblasts as Compared toMdm2SNP309T/T and C57Bl/6 Fibroblasts
P309G/G and Mdm2SNP309T/T mouse embryo fibroblasts (MEFs) isolated from at
with 500nMmithramycin A for 18 hr. Themean and standard error of the mean
he number (n) of different MEF lines indicated.
ndMdm2SNP309T/T lysates were carried out and blotted with Mdm2 and b-actin
EFs () serve as positive and negative controls, respectively.
arate low passage (P2) MEF cell lines per genotype were plated, grown for 1, 3,
an and SEM for three separate MEF lines per genotype.
c.
Figure 4. The Mdm2SNP309G Allele Results in Reduced p53 Activity
(A) Western blots of C57Bl/6 (C), Mdm2SNP309G/G (G/G), and Mdm2SNP309T/T
(T/T) splenic lysates were performed and blotted with Mdm2 and b-actin anti-
bodies. Mdm2/ p53/ splenic lysates () serve as an Mdm2 negative
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CanMdm2 were dramatically different in fibroblasts, mithramycin A
decreased expression of Mdm2 only in Mdm2SNP309G/G MEFs.
Given the differences in Mdm2 levels between the
Mdm2SNP309G/G and Mdm2SNP309T/T MEFs, we tested whether
these differences conferred a growth advantage. We found
that theMdm2SNP309G/G MEFs had an increased rate of prolifer-
ation as compared to the Mdm2SNP309T/T MEFs, with a slope of
0.26 ± 0.029 and 0.15 ± 0.022, respectively (Figure 3C). Thus
early passage Mdm2SNP309G/G MEFs have a growth advantage
as compared to the Mdm2SNP309T/T MEFs.
The p53 Pathway Is Partially Attenuated
in Mdm2SNP309G/G Mice
It is widely appreciated that Mdm2 levels tightly control p53
levels in vivo (Iwakuma and Lozano, 2003). To determine how
small increases inMdm2 levels impact the p53 pathway, we first
examined the levels of Mdm2 and p53 protein in mouse tissues.
Spleens fromMdm2SNP309G/Gmice had elevated levels of Mdm2
protein and consequently lower levels of p53 as compared to
control Mdm2SNP309T/T and wild-type C57Bl/6 mice (Figures 4A
and 4B). To test the functional consequences of lower levels of
p53 in mice harboring the Mdm2SNP309G allele, Mdm2SNP309G/G,
Mdm2SNP309T/T, p53+/, and C57Bl/6 mice were exposed to low
dose (1Gy) ionizing radiation (IR). This dose of IR triggers a robust
p53 response in the thymus (Alvarez et al., 2006). Thymi from
Mdm2SNP309G/G mice exhibited a significantly lower apoptotic
response after low dose IR (13.3 ± 0.77% cleaved caspase-3
positive cells) as compared to the Mdm2SNP309T/T (19.0% ±
3.1% cleaved caspase-3 positive cells) or wild-type C57Bl/6
(24.3 ± 2.0% cleaved caspase-3 positive cells) micecontrol. The mean and SEM of the three control samples was determined by
the ratio between the Mdm2 bands and the corresponding b-actin bands
and arbitrarily set to one. The mean and SEM of Mdm2 in splenic lysates
fromMdm2SNP309G/G andMdm2SNP309T/Tmice was determined by comparing
the ratios of Mdm2/b-actin normalized to the control ratio.
(B) Western blots of C57Bl/6 (C), Mdm2SNP309G/G (G/G), and Mdm2SNP309T/T
(T/T) lysates were carried out and blotted with p53 and b-actin antibodies.
The mean and SEM was determined as above.
(C) Apoptosis was determined by counting the percentage of cleaved cas-
pase-3 positive cells in the thymi of p53+/ (9.1% ± 3.5%), Mdm2SNP309G/G
(G/G) (13.3% ± 0.77%), Mdm2SNP309T/T (T/T) (19.0% ± 3.1%), and C57Bl/6
(C) (24.3% ± 2.0%) mice after 1 Gy ionizing radiation (IR). At least 300 cells
were counted from three randomized high magnification fields per animal.
The mean and SEM for each genotype were calculated from at least three
thymi per genotype. Statistical significance was determined by one-way
ANOVA. n = the number of mice examined for each genotype. The scale bar
represents 50 mm.
(D) Real-time RT-PCR analysis for mRNA levels of the p53-dependent targets
Puma and Ccng1 in the thymus of untreated () Mdm2SNP309G/G (G/G) and
Mdm2SNP309T/T (T/T) mice or Mdm2SNP309G/G (G/G) and Mdm2SNP309T/T (T/T)
mice treated (+) with 1 Gy ionizing radiation. Thymi were harvested from irra-
diated mice 3 hr posttreatment. The mean and SEM were determined from
triplicate samples after normalization to Rplp0 for the number (n) of mice indi-
cated. Statistical significance was determined by unpaired Student’s t test.
(E) Apoptosis was determined by counting the percentage of cleaved cas-
pase-3 positive cells in Mdm2SNP309T/T p53515A/+ and Mdm2SNP309G/G
p53515A/+ thymi. At least 300 cells were counted from three high magnification
fields per thymus per genotype. The mean and SEM of each genotype were
calculated from three separate mice. Statistical significance was determined
by unpaired Student’s t test. n = the number of mice examined for each geno-
type. The scale bar represents 50 mm. See also Figure S3.
cer Cell 18, 220–230, September 14, 2010 ª2010 Elsevier Inc. 223
Cancer Cell
Mdm2SNP309G Directly Influences Cancer Risk(Figure 4C, ANOVA, p = 0.018). In fact, the levels of p53-depen-
dent apoptosis inMdm2SNP309G/G thymi were comparable to p53
heterozygousmice (p = 0.304). These data suggest that the pres-
ence of two Mdm2SNP309G alleles significantly inhibited p53-
dependent apoptosis in response to DNA damage. To examine
the activation of downstream effectors of p53 function, we quan-
tified activation of apoptotic and cell cycle arrest transcriptional
targets of p53 after IR. The pro-apoptotic factor, Puma, and the
cell cycle inhibitor, Ccng1 (the gene that codes for Cyclin G1),
were significantly lower in thymi from irradiated Mdm2SNP309G/G
mice as compared to thymi from irradiated Mdm2SNP309T/T
mice, (p = 0.037 and p = 0.030, respectively) (Figure 4D). Two
other p53 targets, Pig8 and p21, were decreased in thymi iso-
lated from irradiated Mdm2SNP309G/G mice; however, neither
reached statistical significance (Figure S3A). These data suggest
that the presence of the Mdm2SNP309G allele attenuates activa-
tion of the p53 pathway in the thymus after low dose irradiation.
To explore the impact of the Mdm2SNP309G allele on other
tissues exposed to low dose IR, we collected epithelial tissues
from these mice. Several transcriptional targets of p53 were
modestly attenuated in the intestine and breast (female) of
Mdm2SNP309G/G mice, specifically Puma in intestine and p21 in
breast, as compared to the Mdm2SNP309T/T mice after low dose
IR; however, transactivation of no gene reached statistical signif-
icance (Figures S3B and S3C). These results suggest that either
epithelial tissues are less sensitive to low dose IR or that transac-
tivation of p53 targets is tissue specific after exposure to IR.
Lastly, we measured p53 protein levels and phosphorylation in
different tissues after low dose IR. Mdm2SNP309G/G thymus and
breast tissues show lower basal levels of p53 (Figures S3D and
S3E), consistent with our observation of low basal p53 levels in
the Mdm2SNP309G/G spleens (Figure 4B). No statistically signifi-
cant differences were observed in p53 levels 3 hr post-IR (Fig-
ures S3F and S3G). Together, these findings suggest that after
IR the polymorphic Mdm2SNP309 allele has a more prominent
impact on p53 activity rather than on p53 stability.
We also examined the impact ofMdm2SNP309G/G on apoptosis
in a mutant p53 background by crossing the Mdm2SNP309 mice
with mice carrying the p53515A hot-spot mutation that encodes
the p53R172H mutant protein (Lang et al., 2004). Thymi from
Mdm2SNP309G/G p53515A/+ mice also had a significant reduction
in apoptotic cells as compared to the control Mdm2SNP309T/T
p53515A/+ mice after low dose IR (p = 0.03) (Figure 4E). These
data suggest that mice harboring two Mdm2SNP309G alleles
have a diminished p53 response after DNA damage both in
wild-type and heterozygous mutant p53 backgrounds.
Mdm2SNP309G Allele Resulted in Increased Cancer Risk
To investigate the impact ofMdm2SNP309G/G on cancer risk in vivo
we monitored cohorts of Mdm2SNP309G/G, Mdm2SNP309T/T,
Mdm2SNP309G/G p53515A/+, Mdm2SNP309T/T p53515A/+, and
p53515A/+ mice for tumor formation. Tumor burdened and
moribund mice of each genotype were sacrificed and tumors
were harvested for pathological analysis. The overall survival
of Mdm2SNP309G/G mice was reduced as compared to the
Mdm2SNP309T/T mice (p = 0.015) (Figure 5A). Five of ten
Mdm2SNP309G/G mice and one of five Mdm2SNP309T/T mice that
died had obvious tumor involvement (Table 1). Several
Mdm2SNP309G/G and Mdm2SNP309T/T mice died of unknown224 Cancer Cell 18, 220–230, September 14, 2010 ª2010 Elsevier Incauses. Mdm2SNP309G/G p53515A/+ mice also succumbed to
tumors significantly earlier than the Mdm2SNP309T/T p53515A/+
and p53515A/+ mice (p = 0.0005) (Figure 5B). The median overall
survival for the Mdm2SNP309G/G p53515A/+ and Mdm2SNP309T/T
p53515A/+ cohorts was 401 and 482 days, respectively (hazard
ratio = 0.561; confidence interval = 0.408–0.786). These results
indicate that the Mdm2SNP309G allele directly increases cancer
risk.
Mdm2SNP309G Impacts the Mdm2-p53 Axis in Tumors
To explore the molecular events that occur during tumor forma-
tion, we investigated the status of Mdm2 and p53. Immunohisto-
chemical analysis of Mdm2 in tumors isolated from the
Mdm2SNP309 mice showed 48% (10 of 21) of Mdm2SNP309G/G
p53515A/+ tumors expressed Mdm2, whereas only 17% (3 of
18) Mdm2SNP309T/T p53515A/+ tumors expressed Mdm2 (p =
0.041, Figure 5C). Because cells exert tremendous selective
pressure to delete wild-type p53 function during tumorigenesis,
we also tested whether these tumors underwent loss of hetero-
zygosity (LOH) of the remaining wild-type p53 allele. Notably,
32% (10 of 31) of Mdm2SNP309G/G p53515A/+ tumors retained
the wild-type p53 allele compared to only 19% (5 of 26) of
Mdm2SNP309T/T p53515A/+ tumors, although these data were not
statistically significant (Figure 5C). Western blot analysis
revealed that all but one tumor (12 of 13) that retained the wild-
type p53 allele expressed p53, regardless of genotype (Fig-
ure S4A). Additionally, p53 was phosphorylated in all the tumors
that retained both p53 alleles (Figure S4A). In tumors with LOH of
the wild-type p53 allele, 60% (3 of 5) of the Mdm2SNP309G/G
p53515A/+ tumors expressed mutant p53 and 100% (6 of 6) of
the Mdm2SNP309T/T p53515A/+ tumors expressed high levels of
mutant p53 (Figure S6B). Furthermore, 40% (2 of 5) of the
Mdm2SNP309G/G p53515A/+ tumors had high levels of phosphory-
lated mutant p53, whereas 67% (4 of 6) of the Mdm2SNP309T/T
p53515A/+ tumors expressed phosphorylated mutant p53
(Figure S4B).
An examination of p53 targets in tumors revealed that mRNA
levels of p53 targets varied greatly in each tumor, likely as
a consequence of multiple additional genetic alterations occur-
ring during tumorigenesis. However, one p53-dependent pro-
apoptotic target, Perp, was significantly attenuated in the tumors
for the Mdm2SNP309G/G p53515A/+ mice as compared to tumors
from theMdm2SNP309T/T p53515A/+ mice (p = 0.023; Figure S4C).
Mdm2SNP309G Alters Tumor Spectrum
In addition to accelerated tumor onset, Mdm2SNP309G/G and
Mdm2SNP309G/G p53515A/+ mice also developed tumor types
only anecdotally reported in C57Bl/6 or p53515A mice. One
Mdm2SNP309G/Gmouse developed amammary adenocarcinoma
in addition to a lymphoma (Figures 6 A–6D, and Table 1). Three
Mdm2SNP309G/G p53515A/+mice developed mammary adenocar-
cinomas (Figures 6 E–I and Table 1), and one developed a squa-
mous cell papilloma (Figure 6G). Because mammary adenocar-
cinomas have never been detected in our p53 cohorts in
a C57Bl/6 background, we confirmed the breast origin of these
tumors by demonstrating the expression of the estrogen
receptor-a (Figures 6D and 6I). Additionally and similar to
patients with LFS that harbor two Mdm2SNP309G alleles (Bond
et al., 2004), Mdm2SNP309G/G p53515A/+ mice also developedc.
Figure 5. Mice Harboring Two Mdm2SNP309G Alleles have Decreased Survival as Compared to Mice Possessing Two Mdm2SNP309T Alleles
(A) Kaplan-Meier curves indicating survival of Mdm2SNP309T/T and Mdm2SNP309G/G mice. Statistical significance was determined by log rank test.
(B) Kaplan-Meier curves indicating the survival of p53515A/+,Mdm2SNP309T/T p53515A/+, orMdm2SNP309G/G p53515A/+mice. Statistical significance was determined
by log rank test.
(C) Mdm2 expression in tumors fromMdm2SNP309G/G p53515A/+ andMdm2SNP309T/T p53515A/+mice. Forty-eight percent (10 of 21) of tumors fromMdm2SNP309G/G
p53515A/+mice and 17% (3 of 15)Mdm2SNP309T/T p53515A/+mice expressMdm2 (p = 0.041). Statistical significancewas determined by the c2 test. Tumor sections
were considered positive if >10% of the total cells were immunoreactive for Mdm2. The scale bar represents 100 mm.
(D) Loss of heterozygosity (LOH) varies at the p53 locus inMdm2SNP309G/G p53515A/+ andMdm2SNP309T/T p53515A/+ tumors. Exon 5, containing the p53515Amuta-
tion, was sequenced in 31 Mdm2SNP309G/G p53515A/+ and 26 Mdm2SNP309T/T p53515A/+ tumors, respectively. LOH was determined by a >50% reduction of the
wild-type allele, noted by the absence of the G nucleotide at position 515. HET denotes retention of both p53 alleles. See also Figure S4.
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p53515A/+ mice (Figure 6L), recapitulating the human phenotype.
DISCUSSION
The sequencing of the human genome has unveiled the pres-
ence of millions of SNPs (Venter et al., 2001). Deciphering the
effects of individual SNPs in human cancer has proven extremely
challenging given the multitude of SNPs, the number of redun-
dant and overlapping pathways they intersect with, and the
heterogeneous genetic make-up of humans. Since the identifi-
cation of the Mdm2SNP309 allele, multiple studies involving large
numbers of patients diagnosed with cancer have suggested that
the Mdm2SNP309G allele significantly increases cancer risk,
whereas other studies have failed to show such an association.
For less common cancers, such as leukemia, ovarian cancer,
lymphoma, or melanoma, the impact of Mdm2SNP309 is even
less clear given the retrospective nature of these studies and
the small size of the cohorts analyzed.CanTo determine the direct impact of this SNP in tumorigenesis,
we generated two genetically engineered mouse models
carrying either Mdm2SNP309G or Mdm2SNP309T alleles and fol-
lowed both cohorts of animals, prospectively. A critical advan-
tage of this mouse model is that we have controlled for the
cancer phenotype variability that arises from environmental,
stochastic, and modifier gene effects as these mice are
>96% C57Bl/6 and, therefore, isogeneic. Mice carrying two
Mdm2SNP309G alleles had increased levels of Mdm2 mRNA and
protein, decreased p53 levels, and a marked attenuation of
the p53 response after ionizing radiation as compared to
Mdm2SNP309T/T or wild-type C57Bl/6 mice. Our findings suggest
that the presence of the Mdm2SNP309G allele contributes to
accelerated tumor formation and reduction in overall survival in
mice that harbor either wild-type or mutant p53. The observation
that the Mdm2SNP309G allele alone is sufficient to cause an
increased cancer risk in our mouse models supports the retro-
spective studies associating the MDM2SNP309G allele with
enhanced tumorigenesis in humans.cer Cell 18, 220–230, September 14, 2010 ª2010 Elsevier Inc. 225











Sarcoma 0 1 34 15
Fibrosarcoma 0 0 10 2
Leiomyosarcoma 0 0 1 0
Pleomorphic 0 0 2 (1) 0
Osteosarcoma 0 0 13 (2) 6 (1)
Histocytic 0 0 4 5
Spindle Cell 0 0 2 (1) 1
Histiocytoma 0 0 2 0
Ovarian hemangiosarcoma 0 0 1 0
Soft tissue sarcoma 0 1 1 2
Lipoma 0 0 2 1
Chondrosarcoma 0 0 1 0
Lymphoma 4 0 8 1
Adenoma
Lung 0 0 1 0
Hepatocellular 0 0 1 0
Papilloma
Squamous cell 0 0 1 0
Adenocarcinoma
Mammary 1 0 3 0
Hepatocellular 0 0 1 2
Undefined 0 0 3 3
Carcinoma
Salivary carcinoma 0 0 1 (1) 0
Squamous cell 1 0 2 1
Undefined 0 0 4 1
Total 6 1 64 24
Parentheses denote number of metastatic tumors.
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Mdm2SNP309G Directly Influences Cancer RiskFollowing the initial description of the MDM2SNP309 allele, the
actual impact of this SNP on human cancers has been con-
founded by conflicting reports vis-a`-vis its impact on tumorigen-
esis in different tissues, ethnicity, or gender. In our study, signif-
icant differences inMdm2 levels were observed in some tissues
but not others. Additionally, some of the mice that carry two
Mdm2SNP309G alleles developed female cancers such as breast
adenocarcinomas regardless of p53 status. This is at variance
with the findings observed in Mdm2SNP309T/T p53515A/+ control
mice, in which no breast tumors were observed. The develop-
ment of breast cancer is highly unusual in C57Bl/6 mice, partic-
ularly in the absence of an accompanying p53 mutation. These
data suggest there may indeed be tissue specific consequences
resulting from the presence of two Mdm2SNP309G alleles.
Previous studies have shown that forced expression of Mdm2
in murine mammary tissue resulted in increased proliferation
and development of breast cancer (Lundgren et al., 1997). The
finding that some of these C57Bl/6 mice that carry the
Mdm2SNP309G allele also develop breast cancer indicates that
even a slight elevation ofMdm2may result in an increased breast
cancer risk.226 Cancer Cell 18, 220–230, September 14, 2010 ª2010 Elsevier InOur studies emphasize the fact that an 2-fold increase in
Mdm2 in some tissues significantly increases cancer risk.
In comparison, Mdm2 haploinsufficiency (a 2-fold decrease)
enhanced survival in several tumor models, further emphasizing
the sensitivity of p53 regulation by Mdm2 (Alt et al., 2003; Men-
drysa et al., 2006; Terzian et al., 2007). The presence of the
Mdm2SNP309G allele alters the homeostasis of the Mdm2/p53
axis resulting in decreased basal steady state levels of p53.
The most likely explanation is that Mdm2 has the ability to target
p53 for degradation more efficiently than itself. The low steady
state levels of p53 observed in these Mdm2SNP309G/G mice
may have a significant impact on potential tumor formation, as
cells from these tissues may have a greater propensity to give
rise to a fully transformed cell in response to evenminor genomic
insults or mitogenic stimulation. Thus, slight perturbations (up or
down) to the p53 pathway may significantly impact tumor forma-
tion, and perhaps, response to chemotherapy.
In addition to tumor formation, Mdm2 and p53 also regulate
each other in response to DNA damage (Haupt et al., 1997; Kub-
butat et al., 1997; Shieh et al., 1997; Siliciano et al., 1997). Loss of
oneMdm2 allele renders mice harboring wild-type p53 sensitivec.
Figure 6. Mice Harboring TwoMdm2SNP309G Alleles Express High Levels of Mdm2 and Develop a Unique Tumor Spectrum as Compared to
Mice Harboring Two Mdm2SNP309T Alleles
(A–C) Hematoxylin and eosin (H&E) staining of paraffin-embedded sections of tumors fromMdm2SNP309G/G mice. (A) Lymphoma. (B) Squamous cell carcinoma.
(C) Mammary adenocarcinoma.
(D) Immunohistochemistry of estrogen receptor-a positive mammary adenocarcinoma from an Mdm2SNP309G/G mouse.
(E–H) H&E staining of paraffin-embedded sections of tumors fromMdm2SNP309G/G p53515A/+mice. (E) Sarcoma. (F) Squamous cell carcinoma. (G) Squamous cell
papilloma. (H) Mammary adenocarcinoma.
(I) Immunohistochemistry of estrogen receptor-a positive mammary adenocarcinoma from an Mdm2SNP309G/G p53515A/+ mouse.
(J and K) H&E staining of paraffin-embedded sections of tumors fromMdm2SNP309T/T p53515A/+ mice. (J) Sarcoma. (K) Squamous cell carcinoma. The scale bar
represents 50 mm in each figure.
(L) The graph depicts the number of primary tumors inMdm2SNP309G/G p53515A/+ andMdm2SNP309T/T p53515A/+ mice. The number above the bar represents the
percentage of mice that had one primary tumor.
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Mdm2SNP309G Directly Influences Cancer Riskto p53-dependent toxicity after IR (Mendrysa et al., 2003; Terzian
et al., 2007), further emphasizing the importance of Mdm2
dosage on p53-dependent phenotypes. Our finding that steady
state levels of p53 are decreased, coupled with the findings that
p53-dependent apoptosis and transactivation of p53 targets are
lower in Mdm2SNP309G/G mice exposed to IR suggests that
modest increases in Mdm2 levels can disrupt p53 stability and
activity. It is noteworthy that p53 levels were similar in both
Mdm2SNP309G/G and Mdm2SNP309T/T mice after IR, even though
activation of p53 targets was ablated in the Mdm2SNP309G/G
mice, suggesting that stabilization of p53 caused by ionizing
radiation may overwhelm the destabilizing effects of the
Mdm2SNP309G allele on p53. It is therefore tempting to hypothe-
size that normal individuals harboring two Mdm2SNP309G alleles
may be more sensitive to exogenous low level DNA damage
caused by environmental stress due to lower steady state p53
levels. A strength of this Mdm2SNP309G mouse model herein
reported is that it may aid in understanding the complex and
fine-tuned interplay between variants of the p53 pathway (e.g.,Canp53 mutations, Mdm2 SNPs), environmental stresses (e.g.,
carcinogens), response to chemotherapeutic agents, and tumor-
independent variables (e.g., gender) in human cancer.
EXPERIMENTAL PROCEDURES
Generation of Mdm2SNP309G/G and Mdm2SNP309T/TMice
A PCR-based strategy was used to generate a targeting vector containing the
deletion of murine intron 1 with replacement by the human intron 1 harboring
either theG or T nucleotide at position 309. To this end, the human intron 1 was
cloned by PCR amplification of human genomic DNA using chimeric
50-mouse-human-30 forward and reverse primers. The forward primer con-
tained 21 nucleotides upstream of the mouse exon 1-intron 1 junction. Three
additional C nucleotides were added to the 50 end of the forward primer to
create a unique SmaI site. These three C nucleotides were deleted during blunt
end digestion and thus resulted in no additions or alterations to the genome.
The reverse 50 murine-human 30 primer contained 32 nucleotides of the mouse
genome downstream of the mouse intron 1-exon 2 junction. Sequence anal-
ysis of the PCR product confirmed the presence of the G nucleotide at position
309 in the humanMDM2 intron 1 amplicon. The humanMDM2 intron 1 contain-
ing the T nucleotide was generated by site directedmutagenesis. The resultingcer Cell 18, 220–230, September 14, 2010 ª2010 Elsevier Inc. 227
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were used as reverse MEGAprimers along with forward primer 50-CTAGC
GACCATTGCGGTTTCGAG-30 (300 base pairs upstream of murine exon 1).
This resulted in an amplicon containing murine exon 1, human intron 1, and
a portion of murine exon 2. Next, we used PCR to generate a murine amplicon
possessing the remainder of exon 2, intron 3, exon 3, a portion of intron 3,
a LoxP site, and unique BamHI and SalI sites from a pBSK-based plasmid
(B.11) containing genomic murine Mdm2 6 Kb upstream and 2.5 Kb down-
stream of the first ATG in exon 3. Next, 5.7 kb of genomic DNA, upstream of
exon 1, was digested from pBSK-B.11. Four piece ligation was used to
generate the 50 arm in the pGL1-targeting vector containing a PGK-neomycin
and a thymidine kinase cassette. The 30 arm was generated by PCR amplifica-
tion of intron 3. Of importance, the start of the 30 arm is precisely at the end of
the 50 arm. This arm contained a unique SalI site (destroyed during cloning),
a Lox P site, 1 kb of intron 3, and a conserved NheI site. This amplicon was
cloned immediately downstream of the neomycin cassette in the targeting
vector. The resulting plasmids, containing the G or T alleles, were completely
sequenced and contained no mutations. Both targeting constructs were line-
arized with AscI and electroporated into TC-1 embryonic stem (ES) cells. DNA
from G418 and ganciclovir selected ES cells was isolated, digested by SpeI,
and subjected to mini-Southern blot analysis using external 50, 30, and
neomycin probes. Correctly targeted ES cells of the Mdm2SNP309G and
Mdm2SNP309T were expanded and Southern blot analysis was repeated to
confirm the integrity of the locus. These ES cell lines were used for injection
into C57BL/6 blastocysts to generate chimeric mice. Male chimeric mice
from each clone were crossed with C57BL/6 female mice and contributed to
the germline of offspring mice. The resulting heterozygous mice were back-
crossed two generations with C57Bl/6 mice, followed by one cross to
C57Bl/6 females containing the Zp3-cre transgene. Female offspring were
then further backcrossed two additional times to C57Bl/6 mice, followed by
one cross to C57Bl/6 mice harboring the p53515A allele. These mice were
then intercrossed to generate a cohort of heterozygous and homozygous
mice for tumor studies. The background of all mice used in these studies
is >96% C57Bl/6. For mouse embryonic fibroblasts, Mdm2SNP309G/G or
Mdm2SNP309T/T mice were crossed and embryos were collected at 13.5 dpc.
All animal studies were carried out according toM.D. Anderson Cancer Center
and Institutional Animal Care and Use Committee Guidelines for Animal Use
(IACUC) (protocol 079906634).Genotyping Analysis
Tails from mice were genotyped for Mdm2 using forward primers 50-GCATTA
GAGAGTGGTCACTGCGAC-30 and reverse primers 50-GAACAGTGATAGAA
CATCATGTCAC-30 for the Mdm2 alleles and previously described primers
for the p53 alleles (Jacks et al., 1994; Liu et al., 2004). In addition to PCR
genotyping, tail DNA from Mdm2SNP309G/G and Mdm2SNP309T/T mice were
randomly sequenced to confirm the presence of the G or T nucleotide after
amplification using forward primer 50-GGATTTCGGACGGCTCTCG-30 and
reverse primer 50-CGCGCAGCGTTCACACTAG-30. The resulting amplicons
were sequenced using the forward primer.Real-Time RT-PCR
Tissues and tumors were isolated from mice and RNA was extracted using
TRIZOL, followed by DNAaseI treatment. RNA from early passage MEFs
(<P2) was extracted as above. First strand synthesis was carried out per the
manufacturer’s protocol (GE Bioscience) on total RNA isolated from each
tissue. The resulting first strand DNA was amplified in the RT-PCR using
primers for Mdm2 (forward 50-GAAAAGCCTGAGGCTGGTAGAA-30 and
reverse 50-AACATAGGCAACCACCAGGAA-30), Rplp0 (forward 50-CCCT
GAAGTGCTCGACATCA-30 and reverse 50-TGCGGACACCCTCCAGAA-30),
Puma (forward 50-GCGGCGGAGACAAGAAGA-30 and reverse 50-AGTCCCA
TGAAGAGATTGTACATGAC-30), Perp (forward 50-GCTGCAGCCACGCTTTTC
and reverse 50-GGCGAAGAACGAGAGAATGAA-30), Ccng1 (forward 50-GCG
AAGCATCTTGGGTGTGT-30 and reverse 50-TCCTTTCCTCTTCAGTCGCT
TT-3), and Pig8 (forward 50-GGCATCTGTACCATCTCAAAGCT-30 and reverse
50-TCGACGCTGTTCCTCTCTCTTC-30). The RT-PCR primers for p21 have
been previously described (Post et al., 2010). Expression of mRNA was
normalized to expression of Rplp0 in each reaction.228 Cancer Cell 18, 220–230, September 14, 2010 ª2010 Elsevier InRNase Protection Assay
Total RNA from spleens of different mice were hybridized with a 32P radiola-
beled antisense Exon 1–3 Mdm2 probe followed by incubation with RNase
A. The RNA-32P probe complex was resolved on a 5% polyacrylmide gel,
transferred to Whatman paper, and dried. The gel was then exposed on Bio-
Max XRay film.
Cell Culture of MEFs
Early passage MEFs were grown in DMEM supplemented with 15% FCS and
1%penicillin/streptomycin. MEFswere either untreated or treatedwith 500 nM
mithramycin A (Sigma) for 18 hr and then harvested.
Cell Proliferation Assays
Three separate Mdm2SNP309G/G and Mdm2SNP309T/T passage 2 MEF cell lines
were plated at 15,000 cells per triplicate well in a 24-well plate. MTT assay
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] was carried
out on days 1, 3, and 5 as previously published (Jackson et al., 1998). Absor-
bance values were averaged for the triplicate wells for each cell line, and then
the three individual cell lines were grouped and averaged with error bars rep-
resenting standard error of the mean.
Immunoblotting Analysis
Spleens, thymi, breast, tumors, and MEFs were collected and frozen in liquid
nitrogen. Protein extracts were prepared by homogenizing the tissues or cells
in NP-40 lysis buffer supplemented with Complete Protease (Roche) and
phosphatase inhibitors. Soluble proteins were boiled in 23-SDS-sample
buffer, separated by SDS-PAGE, and transferred to PVDF membranes (Milli-
pore). Membranes were incubated with rabbit a-p53 (CM5) (Vector Labora-
tory), mouse a-Mdm2 (2A10) (Calbiochem), rabbit a-phospho-Ser18p53 (Cell
Signaling), mouse a-b-actin (Sigma), or mouse a-vinculin (Sigma) antibodies
and antigen-antibody complexes were detected by the enhanced chemilumi-
nescence Kit (GE Bioscience) or BCIP/NBT Color Development Substrate
(Promega). Determination of band intensity in western blots was carried out
using ImageQuant software (GE Healthcare).
Gamma Irradiation and Thymic Apoptosis Assays
Six-week-oldmicewere treatedwith 1Gy IR and sacrificed 3 hr posttreatment.
Tissues were harvested and frozen in liquid nitrogen. Western blot analysis
was carried out as above. For apoptotic assays, thymi were harvested and
fixed in 10% phosphate buffered formalin (Sigma) followed by paraffin embed-
ding. Serial sections were either stained with hematoxylin and eosin (H&E) or
subjected to immunohistochemistry (IHC). For IHC, sections were deparaffi-
nized and antigens were retrieved using citric acid and steam. IHC was carried
out using rabbit a-cleaved caspase-3 (Cell Signaling) and visualized by ABC
and DAB kits (Vector Laboratories). Slides were counterstained with Nuclear
Fast Red.
Pathological Analysis of Tumors
Moribund mice were sacrificed according to M.D. Anderson Cancer Center
and IACUC guidelines. Euthanized mice were necropsied and tissues were
harvested and fixed in 10% phosphate buffered formalin followed by paraffin
embedding. Tissue sections were stained with hematoxylin and eosin and
morphologic analysis was carried out by the Department of Veterinary Medi-
cine at M.D. Anderson Cancer Center. For IHC, sections were deparaffinized
and antigens were retrieved using citric acid and steam. IHC was carried out
using or rabbit a-Mdm2 (R & D Systems) and visualized by ABC and DAB
kits. Slides were counterstained with Nuclear Fast Red. Breast tumors were
confirmed by immunohistochemistry as above using mouse a-estrogen
receptor-a, 1D5 (Dako).
Sequence Analysis
Loss of heterozygosity at the p53 locus was determined by PCR amplification
of genomic tumor DNA using forward primer 50TACTCT-CCTCCCCTCAA
TAAGCTATTC-30 (exon 5) and reverse primer 50-AGTCCTAACCCCACAG
GCGGTGTT-30 (intron 5). The PCR amplicons were then sequencing using
the exon 5 primer and analyzed using Chromas software.c.
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Comparisons of mean values between the groups were analyzed using Graph-
Pad Instat software (GraphPad Software Inc.). Statistical significance of the
differences was analyzed by using unpaired Student’s t test for comparisons
of two groups, ANOVA for comparisons of more than two groups, or the c2
test for 2 by 2 comparisons. Survival curves were plotted by the Kaplan-Meier
method and compared by the log rank (Mantel-Cox) test using GraphPad
Prism. All p values were two-sided and the level of statistical significance
was set at <0.05.SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and can be found with this
article online at doi:10.1016/j.ccr.2010.07.010.
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